Weselcouch E O, Baird A J, Sleph P, Grover G J
Department of Pharmacology, Bristol-Myers Squibb Pharmaceutical Research Institute, Princeton, New Jersey 08543.
Am J Physiol. 1995 Jan;268(1 Pt 2):H242-9. doi: 10.1152/ajpheart.1995.268.1.H242.
Endothelium-derived nitric oxide (NO) has recently been reported to be a mediator of ischemic preconditioning in dog hearts. The aim of the present study was to determine the role of NO in ischemic preconditioning in isolated perfused rat hearts. Rat hearts were perfused at either constant pressure (80 mmHg) or constant flow. After aerobic perfusion (37 degrees C) for 10 min, hearts were treated with N omega-nitro-L-arginine methyl ester (L-NAME; 30 microM), which is an inhibitor of NO synthase, or vehicle. Ten minutes later, the hearts were preconditioned (4 episodes of 5 min of global ischemia and 5 min of reperfusion) or perfused normally before a 30-min global ischemic period. All hearts were reperfused for 30 min. Coronary flow or perfusion pressure plus heart rate and contractile function were measured continuously. Hearts perfused at constant pressure and treated with 30 microM L-NAME, a concentration that effectively inhibits endogenous NO synthesis, exhibited decreased coronary flow after 10 min, and flow remained decreased throughout the experiment. Ischemic preconditioning before 30 min of global ischemia resulted in a doubling of contractile function and a reduction of lactate dehydrogenase release at the end of the 30-min reperfusion period compared with nonpreconditioned hearts. The protective effect of preconditioning was not different in L-NAME-treated hearts. In addition, inhibition of NO synthase had no effect on the severity of ischemia in nonpreconditioned hearts. Similar results were obtained in preconditioned hearts that were perfused at constant flow, indicating that the flow reductions caused by L-NAME did not influence the results.(ABSTRACT TRUNCATED AT 250 WORDS)
内皮衍生的一氧化氮(NO)最近被报道为犬心脏缺血预处理的介质。本研究的目的是确定NO在离体灌注大鼠心脏缺血预处理中的作用。大鼠心脏在恒压(80 mmHg)或恒流条件下灌注。在37℃有氧灌注10分钟后,心脏用NO合酶抑制剂Nω-硝基-L-精氨酸甲酯(L-NAME;30μM)或溶剂处理。10分钟后,在30分钟全心缺血期之前,对心脏进行预处理(4次5分钟全心缺血和5分钟再灌注)或正常灌注。所有心脏再灌注30分钟。连续测量冠状动脉流量或灌注压加心率和收缩功能。在恒压下灌注并用30μM L-NAME处理的心脏,该浓度可有效抑制内源性NO合成,10分钟后冠状动脉流量降低,并且在整个实验过程中流量持续降低。与未预处理的心脏相比,30分钟全心缺血前的缺血预处理导致收缩功能加倍,并且在30分钟再灌注期结束时乳酸脱氢酶释放减少。L-NAME处理的心脏中预处理的保护作用没有差异。此外,NO合酶的抑制对未预处理心脏的缺血严重程度没有影响。在恒流灌注的预处理心脏中也获得了类似的结果,表明L-NAME引起的流量减少不影响结果。(摘要截断于250字)